Brivaracetam disposition in renal impairment

Journal of Clinical Pharmacology

Volumn 52, Issue 12, 2012, Pages 1927-1933

  Sargentini Maier, Maria Laura ^a   Sokalski, Antoni ^b   Boulanger, Pierre ^a   Jacobs, Tom ^a   Stockis, Armel ^a  

^a UCB PHARMA   (Belgium)

^b Dialysis Unit   (Poland)

Author keywords

brivaracetam; epilepsy; ESRD; pharmacokinetics; renal impairment; ucb 34714

Indexed keywords

BRIVARACETAM; DRUG METABOLITE;

ADULT; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DIZZINESS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG HALF LIFE; DRUG URINE LEVEL; EPILEPSY; EUPHORIA; FEMALE; HEADACHE; HUMAN; KIDNEY CLEARANCE; KIDNEY DISEASE; MALE; MAXIMUM PLASMA CONCENTRATION; PHASE 1 CLINICAL TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; SINUS BRADYCARDIA; SOMNOLENCE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; ANTICONVULSANTS; AREA UNDER CURVE; FEMALE; HUMANS; MALE; MIDDLE AGED; PYRROLIDINONES; RENAL INSUFFICIENCY;

EID: 84863951068     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270011431457     Document Type: Article

References (21)

1. Brodie MJ. Antiepileptic drug therapy the story so far. Seizure. 2010 ; 19: 650-655
2. Gillard M, Fuks B, Leclercq K, Matagne A. Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: relationship to anti-convulsant properties. Eur J Pharmacol. 2011 ; 664: 36-44
3. Kaminski RM, Gillard M, Leclercq K, et al. Proepileptic phenotype of SV2A-deficient mice is associated with reduced anticonvulsant efficacy of levetiracetam. Epilepsia. 2009 ; 50: 1729-1740
4. Zona C, Pieri M, Carunchio I, Curcio L, Klitgaard H, Margineanu DG. Brivaracetam (ucb 34714) inhibits Na+ current in rat cortical neurons in culture. Epilepsy Res. 2010 ; 88: 46-54
5. Matagne A, Kenda B, Michel P, Klitgaard H. UCB 34714, a new pyrrolidone derivative, suppresses seizures epileptogenesis in animal models of chronic epilepsy in vivo. Epilepsia. 2003 ; 44: 53-54
6. Tai KK, Truong DD. Brivaracetam is superior to levetiracetam in a rat model of post-hypoxic myoclonus. J Neural Transm. 2007 ; 114: 1547-1551
7. Matagne A, Margineanu DG, Kenda B, Michel P, Klitgaard H. Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A. Br J Pharmacol. 2008 ; 154: 1662-1671
8. Sargentini-Maier ML, Rolan P, Connell J, et al. Brivaracetam safety, tolerability, pharmacokinetics and CNS pharmacodynamic effects after 10 to 1400 mg single rising oral doses in healthy males. Br J Clin Pharmacol. 2007 ; 63: 680-688
9. Sargentini-Maier ML, Espié P, Coquette A, Stockis A. Pharmacokinetics and metabolism of 14C-brivaracetam, a novel SV2A ligand, in healthy subjects. Drug Metab Dispos. 2008 ; 36: 36-45
10. Rolan P, Sargentini-Maier ML, Pigeolet E, Stockis A. The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after multiple increasing oral doses in healthy men. Br J Clin Pharmacol. 2008 ; 66: 71-75
11. von Rosenstiel P, Perucca E The Treatment of Epilepsy. 3 rd ed.Chichester, UK: Wiley-Blackwell; 2009:447-457. Shorvon S Perucca E Engel J, ed. Chichester, UK: Wiley-Blackwell ; 447-457.
12. Kasteleijn-Nolst Trenité DGA, Genton P, Parain D, et al. Evaluation of brivaracetam, a novel SV2A ligand, in the photosensitivity model. Neurology. 2007 ; 69: 1027-1034
13. van Paesschen W, Brodsky A. Efficacy and tolerability of 50 and 150 mg/day brivaracetam (ucb 34714) as adjunctive treatment in adults with refractory partial-onset epilepsy. Epilepsia. 2007 ; 48: 329
14. French JA, Costantini C, Brodsky A, von Rosenstiel P. Adjunctive brivaracetam for refractory partial-onset seizures: a randomized, controlled trial. Neurology. 2010 ; 75: 519-525
15. Werhahn KJ, Biton V, Johnson ME, Merschhemke M, Lu S. Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: results from two randomized, double-blind, placebo-controlled trials. Epilepsia. 2010 ; 51: 150
16. Sargentini-Maier ML, Homery MC, Stockis A. Pharmacokinetics, safety and tolerability of brivaracetam in healthy elderly subjects. Epilepsia. 2008 ; 49: 452
17. Dreisbach AW. The influence of chronic renal failure on drug metabolism and transport. Clin Pharmacol Ther. 2009 ; 86: 553-556
18. Momper JD, Venkataramanan R, Nolin TD. Nonrenal drug clearance in CKD: searching for the path less traveled. Adv Chronic Kidney Dis. 2010 ; 17: 384-391
19. Nolin TD. Altered nonrenal drug clearance in ESRD. Curr Opin Nephrol Hypertens. 2008 ; 17: 555-559
20. Verbeeck RK, Musuamba FT. Pharmacokinetics and dosage adjustment in patients with renal dysfunction. Eur J Clin Pharmacol. 2009 ; 65: 757-773
21. Zhang Y, Zhang L, Abraham S, et al. Assessment of the impact of renal impairment on systemic exposure of new molecular entities: evaluation of recent new drug applications. Clin Pharmacol Ther. 2009 ; 85: 305-311